Regulation of VEGF/HIF-1 by AKT: Implications for Radiotherapy
AKT 对 VEGF/HIF-1 的调节:对放射治疗的影响
基本信息
- 批准号:7851363
- 负责人:
- 金额:$ 24.92万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2002
- 资助国家:美国
- 起止时间:2002-07-01 至 2013-05-31
- 项目状态:已结题
- 来源:
- 关键词:BindingBlood VesselsClinicClinicalConsensusDataDown-RegulationEGFR inhibitionEpidermal Growth Factor ReceptorEpidermal Growth Factor Receptor Tyrosine Kinase InhibitorErlotinibFigs - dietaryGefitinibGenetic TranscriptionGlycogen Synthase Kinase 3Glycogen Synthase KinasesGoalsGrowthHead and Neck Squamous Cell CarcinomaHumanHypoxiaHypoxia Inducible FactorLeadLiteratureMalignant NeoplasmsMediatingMediator of activation proteinNude MiceOxygen ConsumptionPI3K/AKTPathway interactionsPharmaceutical PreparationsPhosphorylationPhosphorylation SitePlayProteinsProto-Oncogene Proteins c-aktPublishingRadiationRadiation ToleranceRadiation therapyRadiosensitizationRegulationResearch PersonnelRoleRunningSecondary toSerumSignal TransductionSirolimusSp1 Transcription FactorTestingTransactivationTranslationsTumor OxygenationVascular Endothelial Growth FactorsWorkXenograft procedureangiogenesishuman FRAP1 proteinin vivoinhibitor/antagonistkinase inhibitormTOR Inhibitoroverexpressionprogramspromotertissue culturetranscription factortumor
项目摘要
DESCRIPTION (provided by applicant): Our long-term goal is to determine mechanisms by which the PI3K/AKT pathway, which is commonly activated in human cancers, increases expression of vascular endothelial growth factor (VEGF) and hypoxia-inducible factor-la (HIF-la). We also wish to understand what role this may play in the efficacy of EGFR inhibitors, which are currently being used in the clinic. VEGF, a key mediator of angiogenesis, is often overexpressed in human cancers. Hypoxia has long been recognized to be a potent inducer of VEGF expression through the transcription factor HIF-1. We have found that the PI3K/AKT pathway plays an important role in VEGF regulation through at least two different mechanisms. First, the PI3K/AKT pathway increases transcription by increasing binding of the transcription factor Sp1 to the VEGF proximal core promoter. Secondly, the AKT pathway can increase the expression of HIF-1a, which can also lead to increased VEGF transcription, particularly in hypoxia. In Specific Aim 1 we will explore the mechanisms by which AKT leads to increased Sp1-mediated transactivation of the VEGF promoter. In Specific Aim 2 we will study the potential role of glycogen synthase kinase-3p (GSK-3J3), a downstream target of AKT involved in protein translation, on increasing HIF-1 a. A number of drugs are currently being tested in the clinic that may work in part through the mechanisms described above. EGFR inhibitors (e.g. gefitinib, erlotinib) decrease PI3K/AKT signaling and we have found that these inhibitors also decrease HIF-1a and VEGF expression. Our preliminary data suggest that gefitinib may increase tumor oxygenation, which should lead to increased radiosensitization. Therefore, in Specific Aim 3 we will study the effects of EGFR inhibition on HIF-1 a and VEGF expression and on tumor oxygenation in vivo and the effects on radiosensitivity. LAY SUMMARY: We will study how the expression of VEGF, an important mediator of blood vessel growth, is increased in human tumors. The clinical importance of these studies is that EGFR inhibitors currently being used in the clinic may work though these pathways to increase the oxygenation of tumors. Increased oxygenation should make tumors more sensitive to radiation; therefore, our studies may be important in helping to optimize the combination of EGFR inhibitors with radiation.
描述(由申请人提供):我们的长期目标是确定PI 3 K/AKT途径(其通常在人类癌症中被激活)增加血管内皮生长因子(VEGF)和缺氧诱导因子-la(HIF-1a)表达的机制。我们还希望了解这可能在目前临床使用的EGFR抑制剂的疗效中发挥什么作用。VEGF是血管生成的关键介质,通常在人类癌症中过表达。长期以来,低氧被认为是通过转录因子HIF-1诱导VEGF表达的有效诱导剂。我们已经发现PI 3 K/AKT通路通过至少两种不同的机制在VEGF调节中起重要作用。首先,PI 3 K/AKT途径通过增加转录因子Sp1与VEGF近端核心启动子的结合来增加转录。其次,AKT通路可以增加HIF-1a的表达,这也可以导致VEGF转录增加,特别是在缺氧时。在具体目标1中,我们将探讨AKT导致Sp1介导的VEGF启动子反式激活增加的机制。在特异性目的2中,我们将研究糖原合成酶激酶-3p(GSK-3 J3)(参与蛋白质翻译的AKT下游靶点)在增加HIF-1 α中的潜在作用。一些药物目前正在临床上进行测试,这些药物可能部分通过上述机制发挥作用。EGFR抑制剂(例如吉非替尼、厄洛替尼)降低PI 3 K/AKT信号传导,并且我们发现这些抑制剂也降低HIF-1 α和VEGF表达。我们的初步数据表明,吉非替尼可能会增加肿瘤氧合,这将导致增加放射增敏。因此,在具体目标3中,我们将研究EGFR抑制对HIF-1 α和VEGF表达的影响以及对体内肿瘤氧合的影响和对放射敏感性的影响。概述:我们将研究血管内皮生长因子(VEGF)的表达是如何在人类肿瘤中增加的,VEGF是血管生长的重要介质。这些研究的临床重要性在于,目前临床上使用的EGFR抑制剂可能通过这些途径来增加肿瘤的氧合。增加氧合应该使肿瘤对辐射更敏感;因此,我们的研究可能对帮助优化EGFR抑制剂与辐射的组合很重要。
项目成果
期刊论文数量(12)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Modulating the tumor microenvironment to increase radiation responsiveness.
调节肿瘤微环境以提高辐射反应能力。
- DOI:10.4161/cbt.8.21.9988
- 发表时间:2009-11
- 期刊:
- 影响因子:3.6
- 作者:Karar J;Maity A
- 通讯作者:Maity A
Sirolimus as a potential radiosensitizer in squamous cell cancer of the head and neck.
- DOI:10.1002/hed.20898
- 发表时间:2009-03
- 期刊:
- 影响因子:2.9
- 作者:Shinohara, Eric T.;Maity, Amit;Jha, Neha;Lustig, Robert A.
- 通讯作者:Lustig, Robert A.
Epidermal growth factor receptor inhibition modulates the microenvironment by vascular normalization to improve chemotherapy and radiotherapy efficacy.
表皮生长因子受体抑制通过血管正常化调节微环境,从而提高化疗和放疗疗效。
- DOI:10.1371/journal.pone.0006539
- 发表时间:2009-08-06
- 期刊:
- 影响因子:3.7
- 作者:Cerniglia, George J.;Pore, Nabendu;Tsai, Jeff H.;Schultz, Susan;Mick, Rosemarie;Choe, Regine;Xing, Xiaoman;Durduran, Turgut;Yodh, Arjun G.;Evans, Sydney M.;Koch, Cameron J.;Hahn, Stephen M.;Quon, Harry;Sehgal, Chandra M.;Lee, William M. F.;Maity, Amit
- 通讯作者:Maity, Amit
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Amit Maity其他文献
Amit Maity的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Amit Maity', 18)}}的其他基金
Combination of CB101 and radiation therapy in head and neck squamous cell carcinoma
CB101与放射治疗联合治疗头颈部鳞状细胞癌
- 批准号:
10545347 - 财政年份:2022
- 资助金额:
$ 24.92万 - 项目类别:
Regulation of VEGF in Tumors by Ras, EGF and PTEN
Ras、EGF 和 PTEN 对肿瘤中 VEGF 的调节
- 批准号:
6895435 - 财政年份:2002
- 资助金额:
$ 24.92万 - 项目类别:
Regulation of VEGF/HIF-1 by AKT: Implications for Radiotherapy
AKT 对 VEGF/HIF-1 的调节:对放射治疗的影响
- 批准号:
7625242 - 财政年份:2002
- 资助金额:
$ 24.92万 - 项目类别:
Regulation of VEGF/HIF-1 by AKT: Implications for Radiotherapy
AKT 对 VEGF/HIF-1 的调节:对放射治疗的影响
- 批准号:
7416733 - 财政年份:2002
- 资助金额:
$ 24.92万 - 项目类别:
Regulation of VEGF in Tumors by Ras, EGF and PTEN
Ras、EGF 和 PTEN 对肿瘤中 VEGF 的调节
- 批准号:
6547496 - 财政年份:2002
- 资助金额:
$ 24.92万 - 项目类别:
Regulation of VEGF in Tumors by Ras, EGF and PTEN
Ras、EGF 和 PTEN 对肿瘤中 VEGF 的调节
- 批准号:
6605674 - 财政年份:2002
- 资助金额:
$ 24.92万 - 项目类别:
Regulation of VEGF in Tumors by Ras, EGF and PTEN
Ras、EGF 和 PTEN 对肿瘤中 VEGF 的调节
- 批准号:
6760221 - 财政年份:2002
- 资助金额:
$ 24.92万 - 项目类别:
Regulation of VEGF/HIF-1 by AKT: Implications for Radiotherapy
AKT 对 VEGF/HIF-1 的调节:对放射治疗的影响
- 批准号:
7147603 - 财政年份:2001
- 资助金额:
$ 24.92万 - 项目类别:
Regulation of VEGF/HIF-1 by AKT: Implications for Radiotherapy
AKT 对 VEGF/HIF-1 的调节:对放射治疗的影响
- 批准号:
7262609 - 财政年份:2001
- 资助金额:
$ 24.92万 - 项目类别:
相似海外基金
A methodology to connect functionalized gonadal constructs to a chick embryo through mechanically induced blood vessels from an egg
一种通过鸡蛋机械诱导血管将功能化性腺结构连接到鸡胚胎的方法
- 批准号:
24K15741 - 财政年份:2024
- 资助金额:
$ 24.92万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
All-in-One Smart Artificial Blood Vessels
一体化智能人造血管
- 批准号:
EP/X027171/2 - 财政年份:2024
- 资助金额:
$ 24.92万 - 项目类别:
Fellowship
Development of nextgeneration cellular artificial blood vessels for coronary artery bypass surgery using bio-3D printer
使用生物 3D 打印机开发用于冠状动脉搭桥手术的下一代细胞人造血管
- 批准号:
23H02991 - 财政年份:2023
- 资助金额:
$ 24.92万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
ealization of navigation surgery by automatic recognition of stomach and surrounding blood vessels using artificial intelligence
利用人工智能自动识别胃及周围血管,实现导航手术
- 批准号:
23K07176 - 财政年份:2023
- 资助金额:
$ 24.92万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Realtime observation and optical control of living microbial probes in blood vessels
血管内活微生物探针的实时观察和光学控制
- 批准号:
23H00551 - 财政年份:2023
- 资助金额:
$ 24.92万 - 项目类别:
Grant-in-Aid for Scientific Research (A)
Creation of a technique for visualization of stress concentration in blood and blood vessels by combined measurement of photoelasticity and ultrasonic Doppler velocimetry
通过光弹性和超声多普勒测速的组合测量,创建了一种可视化血管中应力集中的技术
- 批准号:
23H01343 - 财政年份:2023
- 资助金额:
$ 24.92万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Shear stress-activated synthetic cells for targeted drug release in stenotic blood vessels
剪切应力激活合成细胞用于狭窄血管中的靶向药物释放
- 批准号:
10749217 - 财政年份:2023
- 资助金额:
$ 24.92万 - 项目类别:
Creation of 3D tissue culture system integrated with blood vessels and autonomic nerves
打造血管与植物神经融合的3D组织培养系统
- 批准号:
23H01827 - 财政年份:2023
- 资助金额:
$ 24.92万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Biological function of osteoporotic drugs on bone-specific blood vessels and perivascular cells
骨质疏松药物对骨特异性血管和血管周围细胞的生物学功能
- 批准号:
22K21006 - 财政年份:2022
- 资助金额:
$ 24.92万 - 项目类别:
Grant-in-Aid for Research Activity Start-up














{{item.name}}会员




